Intersect ENT (XENT) and Neurometrix (NASDAQ:NURO) Head-To-Head Review

Intersect ENT (NASDAQ: XENT) and Neurometrix (NASDAQ:NURO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability and analyst recommendations.

Valuation and Earnings

This table compares Intersect ENT and Neurometrix’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Intersect ENT $78.71 million 13.63 -$25.22 million ($0.63) -57.81
Neurometrix $12.03 million 0.26 -$14.91 million ($17.04) -0.08

Neurometrix has lower revenue, but higher earnings than Intersect ENT. Intersect ENT is trading at a lower price-to-earnings ratio than Neurometrix, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Intersect ENT and Neurometrix, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Intersect ENT 0 2 8 0 2.80
Neurometrix 0 0 1 0 3.00

Intersect ENT presently has a consensus price target of $33.43, suggesting a potential downside of 8.21%. Neurometrix has a consensus price target of $3.00, suggesting a potential upside of 127.27%. Given Neurometrix’s stronger consensus rating and higher probable upside, analysts plainly believe Neurometrix is more favorable than Intersect ENT.

Volatility and Risk

Intersect ENT has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Comparatively, Neurometrix has a beta of 0.21, indicating that its stock price is 79% less volatile than the S&P 500.

Profitability

This table compares Intersect ENT and Neurometrix’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Intersect ENT -19.81% -15.96% -14.16%
Neurometrix -80.57% -232.71% -140.16%

Insider & Institutional Ownership

87.4% of Intersect ENT shares are owned by institutional investors. Comparatively, 12.6% of Neurometrix shares are owned by institutional investors. 13.7% of Intersect ENT shares are owned by company insiders. Comparatively, 4.4% of Neurometrix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Intersect ENT beats Neurometrix on 10 of the 14 factors compared between the two stocks.

Intersect ENT Company Profile

Intersect ENT, Inc. is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care. The Company’s commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. The Company is building a portfolio of products based on its drug releasing bio-absorbable implant technology that are designed to provide localized drug delivery to treat patients across the continuum of care in chronic sinusitis. The Company markets PROPEL, which is indicated for use following ethmoid sinus surgery, and PROPEL Mini, which is indicated for use following ethmoid and/or frontal sinus surgery.

Neurometrix Company Profile

NeuroMetrix, Inc. is a healthcare company combining bioelectrical and digital medicine to address chronic health conditions, including chronic pain, sleep disorders and diabetes. The Company is engaged in the sale of medical equipment, and consumables and accessories. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. Its products include ADVANCE NCS/EMG System (the ADVANCE System), Quell, SENSUS and DPNCheck. Quell is a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems. The SENSUS pain therapy device, the technological predecessor to Quell, is a prescription neuro-stimulation device based on transcutaneous electrical nerve stimulation (TENS) for relief of chronic, intractable pain. DPNCheck is a quantitative nerve conduction test. ADVANCE System is a platform for the performance of traditional nerve conduction studies.

Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply